chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Weird feeling in her heart; Heart hurt; Later that night the patient felt a lot of anxiety; This spontaneous case was reported by a non-health professional and describes the occurrence of CHEST DISCOMFORT (Weird feeling in her heart), CHEST PAIN (Heart hurt) and ANXIETY (Later that night the patient felt a lot of anxiety) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 0441321A and 021C21A) for COVID-19 vaccination.     The patient's past medical history included Sickness (Patient may have had COVID-19.Not diagnosed as COVID-19.) in February 2020.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Apr-2021, the patient experienced CHEST DISCOMFORT (Weird feeling in her heart), CHEST PAIN (Heart hurt) and ANXIETY (Later that night the patient felt a lot of anxiety). At the time of the report, CHEST DISCOMFORT (Weird feeling in her heart), CHEST PAIN (Heart hurt) and ANXIETY (Later that night the patient felt a lot of anxiety) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant information was not provided.Treatment information was not provided.   This case was linked to MOD-2021-406202, MOD-2021-406203, MOD-2021-406090 (Patient Link).
Blister like vesicles with elongated vesicles located 25-30 mm from injection site on both sides.  NOTE: Vesicles are similar to shingles.
This spontaneous report was received from a Nurse Practitioner and refers to multiple patients of unknown age and gender. Medical history and concomitant medications were not provided. On unknown dates, the patients were vaccinated with improperly stored vaccines. The vaccines involved were as follows: GARDASIL 9 (lot # M042853, expiration 17-JUL-2019; lot # M043731, expiration 22-JUN-2019, or lot #  M041212; expiration 21-JUN-2019) ROTATEQ (lot # M043563, expiration 09-JUN-2018; lot # M038208, expiration 04-MAY-2018 or lot # M041184, expiration 31-MAY-2018) LIQUID PEDVAXHIB (lot # M046134, expiration 27-SEP-2019) Temperature: 32 degrees F to 35 degrees F (34.2 degrees F) Time frame: 16 hours, 47 minutes, 30 seconds Previous temperature excursion: yes, on 01-JUN-2017: 32 degrees F to 35 degrees F (35 degrees F0 for 16 hours, 28 minutes; and on 05-JUN-2017: 32 degrees F to 35 degrees F (35 degrees F) for 72 hours; and on 13-JUN-2017: 32 degrees F to 35 degrees F (35 degrees F) for 24 hours. Call was because of a data logger. Please note that the reporter did provide a doses administered worskeet but the patient IDs were retracted and the "shot date" was illegible on the form. No adverse effects were reported. Additional information is not expected.
This spontaneous report was received from a nurse refers to a child patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concomitant medications were not reported. On an unknown date, the patient was vaccinated with improperly stored dose of RECOMBIVAX HB injection 5/0.5 microgram/ml, 0.5 ml once intramuscularly (lot # L048848 and expiration date: 09-AUG-2018) for prophylaxis. No adverse effect reported. There was no product quality complaint (PQC) reported. No further information was obtained. This is one of three reports received from the same reporter. Sender's Comments: US-009507513-1803USA001879: US-009507513-1803USA002040.
Hospitalization for Acute hypoxic respiratory failure due to COVID-19 on dates 7/15/2023-7/20/2023. Treated with dexamethasone, baricitinib, Remdesivir, vitamin C 1,000 mg PO daily, vitamin D 25 mcg PO daily, zinc 50 mg PO daily.
Information has been received from a registered nurse concerning a 19 year old male who on 08/20/2001 and 09/21/2001 was vaccinated with the first and second dose of hep b vaccine recombinant. On 09/21/2001 the mother called the doctor's office to report that about three hours after he received the vaccine he experienced sweating, headache, and his pupils were dilated. Unspecified medical attention was sought. The symptoms lasted about an hour and were relieved without any medical management. The nurse reported that the pt is very anxious when he receives a shot. The mother told the nurse that when he received his first dose on 08/20/2001 he developed similar symptoms. Additional info has been requested.
Fever; Chills; Body Aches; Could hardly get up; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever), CHILLS (Chills), MYALGIA (Body Aches) and FATIGUE (Could hardly get up) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever), CHILLS (Chills), MYALGIA (Body Aches) and FATIGUE (Could hardly get up). At the time of the report, PYREXIA (Fever), CHILLS (Chills), MYALGIA (Body Aches) and FATIGUE (Could hardly get up) outcome was unknown. Not Provided
hi, I had tingling a few hours after receiving the first does of the modern vaccine, mostly in my chin, tongue and lips. I have since then had on and off nueropothy, from severe numbness and tingling throughout my entire body and head, to mild tingling, some of it being so severe, that I could not sleep. My general practioner has advised that I do not get the booster.
Vaccinated at approx: 2:36pm. Known history of anaphylaxis to peanuts, penicillin and shellfish. 2:40- during 30 min observation in clinic, pt reported to RN itching to left chest. No noted redness. Husband at pt side. 2:41-PharmD at pt side.   2:42 Noted perioral redness, pt reports itching to chest now spreading to left neck, onset of left sided headache, redness to right eye, sinus congestion, and hoarseness to voice. PT reports that she took 25 mg Benadryl PO prior to arrival as she was concerned for possible allergic reaction. EMS called by RN.  2:45 Epi pen at pts side. Pt hesitant and refusing epi at this time. Pt alert and oriented, speaking full sentences, no resp distress VS 120/82 HR:85, RR:25 2:50 Pt agreed to Epi pen. Epi pen (lot#OFM407, exp: FEB2022) Administered by PharmD to right upper thigh. Pt tolerated well.  2:51 HR: 97 O2:97% RR: 25, Perioral redness improving. sinus congestion and hoarse voice decreasing, showing sign of improvement. 2:52 EMS arrived, Report given to EMS by PharmD, PT alert pt left with EMS via gurney.
This is a spontaneous report from a Pfizer-sponsored program received from a contactable consumer reporting for her/himself. A patient of unspecified age, race/ethnicity and gender received pneumococcal 13-val conj vac (dipht crm197 protein) (unspecified trade name), via an unspecified route of administration, on an unspecified date, at single dose, for immunisation. Relevant medical history and concomitant medications were not reported. The patient experienced pneumonia on an unspecified date with outcome of unknown. The patient was hospitalized due to the event for 8 days. No follow-up attempts possible. No further information expected. Pfizer is marketing authorization holder of pneumococcal 13-val conj vac (dipht crm197 protein) in the reporter's country. This may be a duplicate report if another marketing authorization holder of pneumococcal 13-val conj vac (dipht crm197 protein) has submitted the same report to the regulatory authorities.
I started experiencing back pain during the fall but it got a lot worse in March 2022.  The pain spread down to my leg.  I went to the ER on 03/28.  I went to the doctor 4/1 and had an MRI on 4/7 and 4/11.  They found a mass on my spine.  I have surgery on 5/9.
Vaccines given 2/15/18 on 2/25/18 mom notices a red area with raised bumps on the Left thigh where the MMRV was given 10 days earlier. Child at clinic.
This spontaneous report as received from a certified medical assistant refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' medical history and concurrent conditions was provided. On unknown dates, the patients were vaccinated with improperly stored doses of VAQTA injection, once, lot # L015460, expiration date: 20-JUL-2017, (dose, dose number, route of administration and injection site were not provided). There were no concomitant medications reported. It was stated that the vaccine underwent temperature excursions of 30 degrees Fahrenheit for 73 hours and 49 degrees Fahrenheit for 25 hours, respectively, that were captured using digital data logger. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Patient's daughter called on the day after the vaccine was administered and reported that patient has hives on hands, stomach and hip.  Patient called doctor's office and left message.  Advised patient to try taking Benadryl.  Advised patient to call doctor if symptoms not improve or get worse.
Evening after getting shot her face swelled Had to take Bendryl - also had fever and severe body aches
Severe chest pains, shortness of breath, when standing heart rate doubles, heart rate 168.
Started about 45-60 minutes after injection.  Fever between 99-100. Nausea. Weakness. Muscle ache. Dizzy. Blurry vision. Headache. Shortness of breath- only for a short time. Feeling faint. Very tired.
Information has been received from a physician concerning a female patient who on an unspecified date was vaccinated with a dose of GARDASIL (Lot number unknown). Subsequently the patient fainted. It was unknown if the patient sought medical attention. At the time of this report the patient's outcome was unknown. This is one of several reports from the same source. Additional information has been requested.
After about 2 weeks I had a red, circular, swollen rash on my arm. It was tender to the touch.
Fever, now up to 100.4 at 8:15 am, achy, sore, lethargic , pain touching or raising arm. headache, shivers,  stomach pain.
Mild to moderate localized soreness upper arm near site of injection without redness or notable swelling lasting  24-36 hours
Redness around injection site; Warmness around injection site; Itchiness around injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness around injection site), VACCINATION SITE WARMTH (Warmness around injection site) and VACCINATION SITE PRURITUS (Itchiness around injection site) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 23-Mar-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness around injection site), VACCINATION SITE WARMTH (Warmness around injection site) and VACCINATION SITE PRURITUS (Itchiness around injection site). At the time of the report, VACCINATION SITE ERYTHEMA (Redness around injection site), VACCINATION SITE WARMTH (Warmness around injection site) and VACCINATION SITE PRURITUS (Itchiness around injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication taken was Calendula Cream.  Patient second dose was scheduled on 11-APR-2021.
Night of 01/26/2011 fever to 101.6 F. Morning of 01/27/2011 noted redness itching and pain in upper left arm where she had received 2 vaccinations.  By morning of 01/28, redness and pain extended to near left wrist. Treated with antibiotics, steroids and antihistamine.
Wife stated patient developed symptoms at approximately 9:15 PM the day of vaccination.  He developed a fever of 102, chills, shortness of breath, and PVC's.  Patient was seen at E.R. for symptoms
first dose in 2020, second on 14-MAY-22; This case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 61-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in 2020).   On 14th May 2022, the patient received the 2nd dose of Shingrix. On 14th May 2022, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK Receipt Date: 20-MAY-2022 Reporters comment: The patient self-reported the case. Received call from agent to transfer caller who reported they received their first dose of Shingrix in 2020 and the second on 14th May 2022. Transfer of consumer was failed and was unable to collect further information.  No further information was available. The reporter did not consent to follow-up. Additional supportive information: The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule.
After waiting the 15 minute observation period, I left. While driving home my eyes started itching and my face felt strange. When I got home I looked in the mirror ni didn?t see a rash or any swelling in my face but then felt my tongue was swollen. I took a Benadryl and called the on call doctor from primary care physicians office and was directed to go to the ER since it was a potentially life threatening reaction.
This spontaneous report as received from a nurse via company representative refers to a female patient of unknown age (reported as adolescent). The patient's medical history and current conditions were not provided. On an unknown date, the patient was vaccinated with a first dose of GARDASIL (lot #, expiration date, strength, dose and frequency were not reported). Secondary suspects and concomitant therapies were not reported. On an unknown date, during a routine vaccination of GARDASIL the patient "passed-out". Therapy with GARDASIL was discontinued as it was reported that the patient will not receive any other doses of GARDASIL. The outcome of loss of consciousness was reported as recovered. The relatedness between "passed-out" and GARDASIL was not reported. Additional information is not expected due to no consent to contact Health Care Professional was given.
pt recvd vax & w/in 40 min of vax, pt devel vomiting, abdo pain & t104; pt taken to er & dx w/ allergic rxn to vax;
EXPIRED VACCINE ADMINISTERED; This spontaneous report received from a pharmacist concerned a 57 year old female of unspecified race and ethnicity. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient had no history of similar event, had no illness at the time of vaccination. The patient had no adverse event after any previous vaccination, no history of allergy to vaccine, drug or food, had no pre-existing acute illness 30 days prior to vaccination, no history of hospitalization in last 30 days, no family history of any disease or allergy. The patient was not pregnant at time of vaccination and was not currently breastfeeding. The patient was previously received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, intramuscular, batch number: 1808978, and expiry: unknown) dose was not reported, 1 total, administered on 09-APR-2021 on left site for prophylactic vaccination. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26.cov2.s.(Dose number in series 1). The patient additionally received booster covid-19 vaccine ad26.cov2.s (Dose number in series 2) (suspension for injection, intramuscular, batch number: 211A21A, expiry: 14-DEC-2021) dose was not reported, 1 total administered on 15-DEC-2021 on left site for prophylactic vaccination. No concomitant medications were reported.  On 15-DEC-2021, the patient was administered with expired vaccine (Dose number in series 2). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of expired vaccine administered was not reported. This report was non-serious. This case, from the same reporter is linked to 20220210382, 20220260967, 20220261011, 20220261042, 20220261039, 20220261092, 20220261043, 20220261022, 20220261000, 20220261048, 20220260995, 20220261014, 20220261063 and 20220261030.
Moderate fatigue; Arm pain; Moderate to mild myalgia; other vaccine same date product: Influenza; other vaccine same date product: Influenza; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP).  A 47-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 24Sep2022 at 17:00 as dose 4 (booster), single (Lot number: GJ6739) at the age of 47 years intramuscular, in left arm for covid-19 immunisation; influenza vaccine (INFLUENZA VACCINE), on 24Sep2022 as dose 1, single (Batch/Lot number: unknown), in right arm for immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. Vaccination history included: Covid-19 vaccine (Primary immunization completed (Manufacturer Unknown)), for Covid-19 immunization; Covid-19 vaccine (DOSE 3 (BOOSTER), SINGLE (Manufacturer Unknown)), for Covid-19 immunization. The following information was reported: OFF LABEL USE (non-serious), PRODUCT USE ISSUE (non-serious) all with onset 24Sep2022, outcome "unknown" and all described as "other vaccine same date product: Influenza"; PAIN IN EXTREMITY (non-serious) with onset 24Sep2022 at 22:00, outcome "not recovered", described as "Arm pain"; FATIGUE (non-serious) with onset 24Sep2022 at 22:00, outcome "not recovered", described as "Moderate fatigue"; MYALGIA (non-serious) with onset 24Sep2022 at 22:00, outcome "not recovered", described as "Moderate to mild myalgia". Therapeutic measures were not taken as a result of fatigue, pain in extremity, myalgia. Additional Information: The patient took over the counter and prescription medications in two weeks. The patient has not been diagnosed with covid prior vaccination and has not tested for covid post vaccination. The patient has no known allergies. The patient experienced arm pain very mild on day of vaccination, then moderate the date following vaccination; moderate to mild myalgia - mild day of vaccination and moderate day following vaccination and moderate fatigue. Based on previous experience with the vaccine recipients are likely to resolve within 48-72 hours post-dose.
19 year old daughter who received the 1st dose of Pfizer COVID vaccine and contracted COVID 5 days later; This is a spontaneous report from a contactable Physician via a medical information team.  A 19-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection) via unspecified route of administration on unspecified date at single dose for covid-19 immunization. Patient medical history and concomitant medications were not reported. Physician mentioned that her sister from another country who was also a Physician emailed Pfizer last week to inquire about her 19-year-old daughter who received the first dose of Pfizer COVID vaccine and contracted COVID-19 5 days later on an unspecified date. She says that she was scheduled to receive her second dose 90 days later due to this. She was asking if it was pertinent to wait those 90 days. The clinical outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
fever max of 102 on 16MAR99 evening-fever 17MAR99 mom found child in resp arrest, unresponsive;initiated CPR-child responded in 2min, had sz, spent day in ER;
Patient had low grade fever of 99 degrees on 12/30/11 at 7pm. Temperature increased to 102.5 and went into ER at midnight. Patient's s/sx, dizziness, aching, headache, and some blurry vision. Patient was given IV fluid since admitted to ER.
8 days after vaccine developed cellulitis out of the blue with no abrasions or bites. Not sure if it is related but I have never experienced this before.
arm soreness; chills; weakness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm soreness), CHILLS (chills) and ASTHENIA (weakness) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012M20A and 032M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced PAIN IN EXTREMITY (arm soreness), CHILLS (chills) and ASTHENIA (weakness). At the time of the report, PAIN IN EXTREMITY (arm soreness), CHILLS (chills) and ASTHENIA (weakness) outcome was unknown.            No relevant concomitant medication was reported.  Treatment information was not provided.   This case was linked to MOD21-046339 (Patient Link).
No adverse reaction reported by patient. She came in wanting the 2nd dose but upon looking out system she was given Varivax instead.
Administered expired dose; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administered expired dose) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Jan-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Jan-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administered expired dose). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administered expired dose) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications details were not reported by the reporter. It was reported that one dose expired of vaccine was administered by mistake. Treatment details was not reported by the reporter.
Generalized rash, arthralgia, fever. Treated with mediol dose pack and Tylenol. Symptoms x 1 week  Vaccine manufact information not recorded in the hospital medication record.
PATIENT GO MODERNA FOR FIRST DOSE. SHE CAME FOR 2ND DOSE. GAVE PFIZER BY MISTAKE.